Novartis (NYSE:NVS) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why

Novartis AG (NYSE:NVS) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $151.40 and traded as high as $154.24. Novartis shares last traded at $153.9290, with a volume of 2,816,193 shares traded.

Novartis News Roundup

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Raised 2026 core-profit outlook: Novartis increased its forecast for full-year core operating income, citing sales growth and productivity improvements. Management also maintained its outlook for full-year sales growth. Novartis Q3 Profit Sinks 70% Despite Sales Growth; Lifts FY26 Core Income View, Backs Sales Outlook
• Positive Sentiment: Quarterly earnings beat estimates: Novartis reported adjusted earnings of $2.46 per share, above the $2.25 consensus, while revenue increased year over year. Growth from Kisqali, Kesimpta and Scemblix helped offset generic-drug pressure. NVS Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
• Neutral Sentiment: Analyst estimates remain broadly constructive: Erste Group Bank made only small changes to its forecasts, trimming its 2026 EPS estimate to $9.16 from $9.24 while raising its 2027 estimate to $9.81 from $9.80. Both remain above the broader current-year consensus of $8.91.
• Negative Sentiment: Reported profit fell sharply: Third-quarter net profit declined about 70%, largely because of a roughly $1.9 billion impairment charge and higher expenses. Although the charge is nonrecurring, it weakened headline results and may be contributing to investor caution. Novartis Raises Guidance Despite Trial Setbacks Hitting Profit
• Negative Sentiment: Execution concerns remain: Kisqali, one of Novartis’ key growth medicines, reportedly fell short of expectations, while generic competition continues to erode sales. Recent clinical-trial setbacks also add uncertainty around the company’s pipeline and future growth.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on NVS shares. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis in a research note on Sunday, August 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “neutral” rating on shares of Novartis in a report on Thursday, September 17th. Citigroup reiterated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Jefferies Financial Group reiterated a “neutral” rating on shares of Novartis in a report on Thursday, July 23rd. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research report on Thursday, October 22nd. Six investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $147.00.

Novartis Stock Performance

The firm has a 50 day moving average of $148.31 and a two-hundred day moving average of $151.61. The stock has a market cap of $297.49 billion, a P/E ratio of 23.52, a P/E/G ratio of 2.74 and a beta of 0.41. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.25 by $0.21. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.53 billion. During the same quarter in the previous year, the firm posted $2.25 earnings per share. Novartis’s revenue was up 4.4% compared to the same quarter last year. On average, research analysts predict that Novartis AG will post 8.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Novartis

A number of hedge funds and other institutional investors have recently made changes to their positions in NVS. Canopy Partners LLC lifted its stake in Novartis by 1.9% during the third quarter. Canopy Partners LLC now owns 3,525 shares of the company’s stock worth $503,000 after purchasing an additional 67 shares during the period. Soltis Investment Advisors LLC lifted its position in Novartis by 20.6% during the 3rd quarter. Soltis Investment Advisors LLC now owns 2,848 shares of the company’s stock worth $406,000 after buying an additional 487 shares in the last quarter. Financial Network Wealth Advisors LLC grew its stake in shares of Novartis by 35.3% during the third quarter. Financial Network Wealth Advisors LLC now owns 452 shares of the company’s stock valued at $64,000 after purchasing an additional 118 shares during the last quarter. Lynx Investment Advisory increased its stake in shares of Novartis by 41.0% in the 3rd quarter. Lynx Investment Advisory now owns 2,409 shares of the company’s stock valued at $343,000 after buying an additional 700 shares during the period. Finally, Laurel Wealth Advisors LLC acquired a new stake in Novartis in the third quarter worth about $125,000. 13.12% of the stock is owned by institutional investors.

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.